Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice TargetHot
Truist Securities analyst Danielle Brill maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $560 to $565.
Truist Securities analyst Danielle Brill maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $560 to $565.